Viracta Therapeutics Raises $18.4M From NantKwest, Others

San Diego-based Viracta Therapeutics, a developer of treatments for cancer caused by Epstein-Barr Virus (EBV) and other viral diseases, has raised $18.4M from Culver City-based NantKwest, one of the biotech firms led by billionaire Dr. Patrick Soon-Shiong. The two said the Series B Preferred financing round also included Wicklow Capital, with Latterell Venture Partners and Forward Ventures also participating. Soon-Shiong joins Viracta's Board of Directors as Vice Chairman as part of the investment deal, and Viracta has also signed an exclusive license to its Phase 2 drug candidate to NantKwest.